- Health & Pharmaceuticals›
- Pharmaceutical Products & Market›
Unbranded generics revenue top corporations in U.S. 2016-2017
Premium statistics
Industry-specific and extensively researched technical data (partially from exclusive partnerships).
A paid subscription is required for full access.
Unbranded generics revenue top corporations in U.S. 2016-2017
Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*
by Matej Mikulic,
last edited
Nov 8, 2018
This statistic depicts the leading unbranded generic corporations in the U.S. between December 2016 and November 2017, by revenue through non-discounted spending. Teva was the largest
unbranded generic corporation with a revenue of eight billion U.S. dollars.
Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*
| Revenue in billion U.S. dollars | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| Revenue in billion U.S. dollars | |
|---|---|
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
| - | - |
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
Exclusive content
Exclusive Premium statistic
You need a Premium Account for unlimited access.
Full access to 1m statistics
Incl. source references
Available to download in PNG, PDF, XLS format
Premium Account
only $49 / month
*
© Statista 2019
About this statistic
Show source
Download
Settings
Share
Chart type
Datalabels
Share on Social Media
Download started
Please be patient - this may take a moment
Please be patient - this may take a moment
Description
Source
More information
by Matej Mikulic,
last edited
Nov 8, 2018
This statistic depicts the leading unbranded generic corporations in the U.S. between December 2016 and November 2017, by revenue through non-discounted spending. Teva was the largest
unbranded generic corporation with a revenue of eight billion U.S. dollars.
- Show sources information
- Show publisher information
- Release date
- February 2018
- Region
- United States
- Survey time period
- December 2016 to November 2017
- Supplementary notes
- * Based on unbranded generic non-discounted spending. Moving annual total November 2017.
Source
- Show sources information
- Show publisher information
- Release date
- February 2018
More information
- Region
- United States
- Survey time period
- December 2016 to November 2017
- Supplementary notes
- * Based on unbranded generic non-discounted spending. Moving annual total November 2017.
Other statistics on the topic
Pharmaceutical Industry in the U.S.
+Pharmaceutical Products & Market
Pharmaceutical market: worldwide revenue 2001-2018
+Pharmaceutical Products & Market
Revenues of leading global generics manufacturers 2018
+Pharmaceutical Products & Market
U.S. brand and generic prescription drug revenue 2005-2018
+Pharmaceutical Products & Market
Pfizer's revenue by segment 2014-2018
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account!
Premium Account
Your perfect start with Statista
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$49 / Month *
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract.
Prices do not include sales tax.
Prices do not include sales tax.
Leading companies trust Statista:
Related Studies: Available to Download in PDF or PPTX Format
All Information
in one Presentation
U.S. pharmaceutical industry
- 99 page/s
- English
- pptx
- Detailed references
Everything On "U.S. pharmaceutical industry" in One Document: Edited and Divided into Handy Chapters. Including Detailed References.
Other Reports & Dossiers
Statista has been my savior on several occasions. The site is easy to maneuver and the data is in a format that can go right into a report or presentation.Marlene Greenfield
Vice President, Hearst Magazines
Statistics on "Generics and biosimilars"
- Global overview
The most important statistics
- Revenue of the worldwide pharmaceutical market from 2001 to 2018 (in billion U.S. dollars)Pharmaceutical market: worldwide revenue 2001-2018
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)Total worldwide generic prescription drug revenue 2010-2024
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024Global generic prescription drug revenues as share of prescribed revenue 2010-2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*Patent expiration risks for total worldwide prescription drug revenue 2010-2024
- Top companies
The most important statistics
- Top generics manufacturers based on revenue in 2018 (in billion U.S. dollars)*Revenues of leading global generics manufacturers 2018
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)Teva Pharmaceutical Industries' generic revenues by region 2016-2018
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)Novartis revenue 2014-2018 by segment
- Pfizer's revenue in 2014 and 2018, by segment (in million U.S. dollars)*Pfizer's revenue by segment 2014-2018
- U.S. market
The most important statistics
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2018 (in billion U.S. dollars)*Brand and generic prescription medication revenue in the U.S. 2006-2018
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018U.S. brand and generic prescription drug revenue 2005-2018
- Change in branded and generic medication spending in the United States from 2013 to 2018 (in billion U.S. dollars)*Spending change on branded and generic medicines in the U.S. 2013-2018
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*Unbranded generics revenue top corporations in U.S. 2016-2017
- Top companies based on unbranded generics U.S. market share during 2016-2017*Unbranded generics market share top corporations in U.S. 2016-2017
- Top 20 U.S. pharma products by dispensed prescriptions in 2018 (in millions)Top U.S. pharma products by prescriptions 2018
- Patent expiration
The most important statistics
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)Projected sales at risk due to patent expiry 2009-2022
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018Top pharma companies by sales loss due to patent loss until 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*Forecast of new brand and LOE impact on growth of developed pharma markets 2018-2022
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*Top branded biologic drugs in the U.S. that will go generic by 2028
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014Time from brand drug launch to generic patent challenges U.S. 1995-2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)Comparison of pre-expiry and generic price for drugs U.S. 2015
- Savings
The most important statistics
- Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)Savings through generic drug usage in the U.S. 2008-2018
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)Total savings of top generic drugs in U.S. 2017
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*Saving of U.S. costs through generic pharmaceuticals by therapy 2017
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)Savings through generic drug usage in the U.S., by age group 2017
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)Savings through generic drug usage in the U.S., by payer 2017
- Percentage of savings through generic drug usage in the United States in 2017, by payerPercentage savings through generic drug usage in the U.S. by payer 2017
- Percentage of savings through generic drug usage in the United States in 2017, by age groupSavings through generic drug usage in the U.S., by age group share 2017
- Biosimilars
The most important statistics
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)Cumulative potential biosimilars market in EU5 countries and the U.S. 2016-2020
- Number of biosimilars in development worldwide as of October 2017, by country Country-wise biosimilar pipelines number in development worldwide 2017
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)Reduction in U.S. direct spending on originator biologics as of 2018
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017Share of filgrastim sales attributable to Neupogen or biosimilars US 2015-2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*Opinion on drug spending reduction due to biosimilars for specialty drugs 2017-2020
- Example of physician office payment for biosimilars in Medicare Part B as of 2019 (in U.S. dollars)*Physician office payment for biosimilars in Medicare Part B in 2019
Discover Statista
Need help with using Statista for your research?
Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statistics
- Growing unbranded generic corporations by absolute Rx growth U.S. 2017
- Nichi-Iko's domestic sales revenue generics FY 2012-2017
- Revenues of leading generics manufacturers
- Nichi-Iko's market share generics in Japan FY 2008-2021
- Nichi-Iko's coverage medical institutions Japan FY 2018, by type
- Nichi-Iko's drug sales share in Japan FY 2018, by institution
- Nichi-Iko's sales share of generics in Japan FY 2012-2017
- Sawai's coverage medical institutions Japan FY 2018, by type
- Nichi-Iko's drug sales distribution in Japan FY 2017, by category
- Sawai's drug sales share in Japan FY 2016, by institution
- Share of top generic purchasing operations in U.S. 2017
- Generic market share value change worldwide 2006 vs. 2016, by region
- Adjusted and unadjusted generic prescription growth in U.S. 2013-2017
- Medicaid program savings through generic drug usage by U.S. state 2015
- Generic market share change in unit volume worldwide 2006 vs. 2016, by region
- Share value of the generic pharmaceuticals market in Portugal 2000-2017
- Volume share of unbranded FMCG in India - by type 2016
- U.S. and Mexico's capacity of corporate renewable deals made by entrants 2015
- Share of U.S. brand drugs meeting patent challenge before generic entry 1995-2014
- Global jewelry sales share from 2003 to 2020, by branding
Studies
- Celgene Corporation - 2018 Form 10-K
- Generic Pharmaceutical Industry Yearbook 2016
- Value and Innovation Framework Report 2019
- Sobi Anual and sustainability report 2017
- Pharmaceutical industry in Italy
- Pharmaceutical trends in Europe
- Teva - 2018 Form 10-K
- Biotechnology in Germany
- PAGB Annual Review 2017-2018
- Indicatori Farmaceutici
- Novo Nordisk ANNUAL REPORT 2017
- Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans, 2006 to 2013
Statistics on "Generics and biosimilars"
- Revenue of the worldwide pharmaceutical market from 2001 to 2018 (in billion U.S. dollars)
- Worldwide total generic prescription drug revenue from 2010 to 2024 (in billion U.S. dollars)
- Worldwide generic prescription drug revenue as a percent of total prescribed revenue from 2010 to 2024
- Worldwide total prescription drug revenue at risk from patent expiration from 2010 to 2024 (in billion U.S. dollars)*
- Top generics manufacturers based on revenue in 2018 (in billion U.S. dollars)*
- Generic revenues of Teva Pharmaceutical Industries from 2016 to 2018, by region (in million U.S. dollars)
- Novartis AG's revenue from 2014 to 2018, by segment (in billion U.S. dollars)
- Pfizer's revenue in 2014 and 2018, by segment (in million U.S. dollars)*
- Brand and generic prescription medication revenue in the U.S. from 2006 to 2018 (in billion U.S. dollars)*
- Proportion of branded versus generic prescription drug revenues in the United States from 2005 to 2018
- Change in branded and generic medication spending in the United States from 2013 to 2018 (in billion U.S. dollars)*
- Top generic drug companies by unbranded generics revenue in the U.S. in 2016-2017 (in billion U.S. dollars)*
- Top companies based on unbranded generics U.S. market share during 2016-2017*
- Top 20 U.S. pharma products by dispensed prescriptions in 2018 (in millions)
- Small molecules sales at risk due to patent expirations in the U.S. from 2009 to 2022 (in billion U.S. dollars)
- Leading pharmaceutical companies based on sales loss due to patent risk until year-end 2018
- Forecast of new brand and brand loss of exclusivity (LOE) impact on growth in developed pharmaceutical markets from 2018 to 2022 (in billion U.S. dollars)*
- Selected top branded biologic drugs in the United States that will go generic between 2016 and 2028, by revenue (in billion U.S. dollars)*
- Time from launching a brand drug to meeting a paragraph IV patent challenge in the U.S. from 1995 to 2014
- Comparison of brand pre-expiry price and generic price of selected drugs in the United States as of 2015 (in U.S. dollars)
- Savings through generic drug usage in the United States from 2008 to 2018 (in billion U.S. dollars)
- Top generic drugs based on savings in the United States in 2017 (in million U.S. dollars)
- Cost savings through generics in the United States in 2017, by therapeutic area (in billion U.S. dollars)*
- Savings through generic drug usage in the United States in 2017, by age group (in billion U.S. dollars)
- Savings through generic drug usage in the United States in 2017, by payer (in billion U.S. dollars)
- Percentage of savings through generic drug usage in the United States in 2017, by payer
- Percentage of savings through generic drug usage in the United States in 2017, by age group
- Cumulative potential biosimilars market in EU-5 countries and the U.S. between 2016 and 2020 (in billion euros)
- Number of biosimilars in development worldwide as of October 2017, by country
- Projected reduction in U.S. biosimilar direct spending on originator biologics as of 2018 (in billion U.S. dollars)
- Filgrastim market share of Neupogen and its U.S. biosimilar competitors from 2015 to 2017
- Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017
- Percentage of U.S. health care executives who foresee biosimilars reducing drug spend for specialty drugs in 2017-2020*
- Example of physician office payment for biosimilars in Medicare Part B as of 2019 (in U.S. dollars)*
- Fastest growing U.S. unbranded generic corporations in 2017 by absolute prescription growth (in millions)
- Domestic generics sales value of Nichi-Iko Pharmaceutical Co., Ltd. in Japan in fiscal years 2012 to 2017 (in billion Japanese yen)
- Revenues of the leading generics manufacturers worldwide in 2009 (in billion U.S. dollars)
- Domestic generics market share of Nichi-Iko Pharmaceutical Co., Ltd. in Japan in fiscal years 2008 to 2021
- Coverage of medical institutions by Nichi-Iko Pharmaceutical Co., Ltd. in Japan in fiscal year 2018, by institution type
- Share of drug sales of Nichi-Iko Pharmaceutical Co., Ltd. in Japan in fiscal year 2018, by medical institution
- Sales share of generics on the Japanese domestic market of Nichi-Iko Pharmaceutical Co., Ltd. in fiscal years 2012 to 2017
- Coverage of medical institutions by Sawai Pharmaceutical Co., Ltd. in Japan in fiscal year 2018, by institution type
- Distribution of drug sales on the Japanese domestic market of Nichi-Iko Pharmaceutical Co., Ltd. in fiscal year 2017, by category
- Share of drug sales of Sawai Pharmaceutical Co., Ltd. in Japan in fiscal year 2016, by medical institution
- Distribution of top generic purchasing operations in the U.S. in 2017
- Change in the value of generics market share worldwide between 2006 and 2016, by region
- Adjusted and unadjusted generics prescription volume growth in the U.S. from 2013 to 2017
- Savings through generic drug usage in Medicaid during 2015, by state (in million U.S. dollars)
- Change in the unit volume of generics market share worldwide between 2006 and 2016, by region*
- Market value share of generic pharmaceuticals in Portugal from 2000 to 2017
- Volume share of unbranded fast moving consumer goods (FMCG) in India in 2016, by type
- Capacity of corporate renewable deals made by entrants in Mexico and the United States in 2015, by major buyer (in megawatts)*
- Percentage of brand drug products that have experienced a drug patent challenge before generic entry from 1995 to 2014
- Worldwide jewelry sales share from 2003 to 2020, by branding
Statista Accounts:
Access All Statistics. Starting from $588 / Year
Related topics
About Statista
Statista offers dossiers and reports on over 170 industries. With Statista you are always able to make informed decisions and boost your work efficiency.
Internet & Telecommunications
- Social Media
- E-Commerce
- Online Video & Entertainment
- Advertising & Marketing
Consumer Goods & FMCG
- Alcoholic Beverages
- Cleaning Products
- Cosmetics & Personal Care
- Food & Nutrition
Retail & Trade
- Health & Hygiene
- International Trade
- Shopping Behavior
- Sports & Leisure
Travel, Tourism & Hospitality
- Business Travel
- Leisure Travel
- Accomodation
- Restaurants
Society
- Demographics
- Economy
- Education & Science
- Politics & Government
Transportation & Logistics
- Aviation
- Rail Transport
- Vehicles & Road Traffic
- Water Transport
Save statistic in .XLS format
You can only download this statistic as a Premium user.
Save statistic in .PNG format
You can only download this statistic as a Premium user.
Save statistic in .PDF format
You can only download this statistic as a Premium user.
Show source references
As a Premium user you get access to the detailed source references and background information about this statistic.
Show details about this statistic
As a Premium user you get access to background information and details about the release of this statistic.
Bookmark statistics
As soon as this statistic is updated, you will immediately be notified via e-mail.
Change statistics options
You need at least a Premium Account to use this feature.
Exclusive Corporate feature
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.